Hemophilia Treatment Market

Hemophilia Treatment Market

Global Industry Analysis (2019 - 2021) - Growth Trends and Market Forecast (2022 - 2027)

Published Date: May 2022 | Format: | No. of Pages: 196

Industry: Pharmaceuticals & Biotechnology | Author Name: Sayali

The global hemophilia treatment market registered revenue worth US$14,785.4 Mn in 2021 and is set to witness robust revenue growth between 2022 and 2027. Fairfield Market Research indicates that the global hemophilia treatment market will rise at a healthy pace of 5.2% CAGR during the period of assessment (2022-2027), reaching market value of US$21,349.6 Mn.

Demand for Hemophilia Treatment to Grow Strong Owing to Significantly Increasing Prevalence of Blood Clotting and Bleeding Related Diseases

Hemophilia is a rare X-linked recessive bleeding disorder wherein the blood does not clot properly due to lack of, or absence of a protein called clotting factor. It is known to occur in a relatively small population across the globe, and thus is classified as a rare/orphan disease. There are three main types namely, hemophilia A, hemophilia B, and acquired hemophilia. Approximately 70% of hemophilia cases are inherited. Hemophilia A accounts for 80-85%, and hemophilia B 15-20% of all the hemophilia cases. Perpetually rising prevalence of the diseases related to blood clotting and bleeding coupled with rise in testing is resulting in growth of the target population.

Fairfield

Introduction of Novel Therapeutics to Primarily Drive Market Growth

Novel therapeutics viz; extended half-life factor concentrates (FVIII/FIX), biphasic antibodies (FVIII mimetics), targeting of natural anti-coagulant pathways, and gene therapy/editing to improve the treatment of people with hemophilia. The advent of newer clotting factor concentrates (CFCs) with extended half-life has not only led to decreased burden of care for patients; more importantly, extended half-life CFCs have made it possible to maintain significantly higher factor trough levels on regular replacement therapy than has been possible with standard half-life CFCs. However, all the factor concentrate-based approaches currently require intravenous infusion and will be ineffective in those with FVIII/FIX inhibitors and will result in allo-antibody formation in some patients. Solid efficacy, and more convenient dosing are thus allowing Hemlibra (emicizumab) to take market share away from older hemophilia treatments.

Lucrative Growth Opportunities Arise in Hemophilia Treatment Market with Development of Safe and Effective Gene Therapy Solutions

Several hemophilia gene therapies are poised to enter late-stage clinical trials in the coming time. Resolving the challenges in hemophilia gene therapy would rapidly pave a path for this new treatment alternative. More recently, the use of molecular genetic information has successfully been applied to deliver human hemophilia gene therapy. Apparently, development of successful gene therapies for hemophilia A and B face different challenges. Applying gene therapy to hemophilia A is more challenging. Hemophilia B has thus always been the focus of biotech companies since most big pharma efforts were engaged with the bigger hemophilia A market. Promising prospects of personalised medication is thus expected to contribute to the growth of hemophilia treatment market to a large extent.

Developed Countries Hold a Majority Market Share, Market to See Phenomenal Growth in Asia Pacific

Presence of major market players in North American, and European countries is contributing to the highest revenue generation in these regions. Moreover, higher spending capacity, availability of government rebates, and high awareness about the available treatment options are driving the growth of hemophilia treatment market in North America, and Europe. While Asia Pacific is expected to showcase the fastest growth rate owing to availability of advanced treatments at comparatively cheaper price in addition to the constantly rising patient population. Asia Pacific is expected to witness highest CAGR of 7.2% during the forecast period.

High Treatment Costs, and Reluctance in Adopting Advanced Therapies to Hinder Market Growth

Relative lack of awareness, and inadequacy of reliable and cost-effective treatment solutions especially in developing economies, continue to hinder the growth of hemophilia treatment market. Inadequate safety, and efficacy of the newly-launched treatments will further continue to limit the growth of hemophilia treatment market through the forecast period. Lack of willingness by patients to switch from the established treatment, and high cost of novel treatment limiting the demand for advanced hemophilia care. In addition, advanced treatments are expensive with no or limited government rebate resulting in higher out of pocket cost, which is restraining adoption of advanced treatment in a larger patient population. The Centers for Disease Control and Prevention (CDC) estimates that about 1,500 people with hemophilia in the US are living with an inhibitor, and the presence of inhibitors adds more than $800,000 per year to their treatment. For the entire population, this amounts to excess healthcare costs of nearly US$1.4 Bn per year.

Key Market Players Prioritise R&D, and Geographic Expansion to Strengthen Global Market Positioning

The top players holding substantial shares in global hemophilia treatment market include Bayer AG, BioMarin Pharmaceuticals, Inc., F. Hoffman La Roche Ltd., Grifols S.A., Sanofi, Takeda Pharmaceuticals Company Ltd., CSL Behring, Medexus Pharmaceuticals Inc., Novo Nordisk, Octapharma AG, and Pfizer Inc.

The hemophilia treatment market has been segmented as below:

By Disease

  • Hemophilia A
    • Severe
    • Moderate
    • Mild
  • Hemophilia B
    • Severe
    • Moderate
    • Mild

By Product

  • Recombinant Factor Concentrates
    • Factor VIII
    • Factor IX
  • Plasma-derived Factor Concentrates
    • Factor VIII
    • Factor IX
  • Extended Half-life Products
    • Factor VIII
    • Factor IX
  • Others

By Patient

  • Pediatric
    • 0 to 4
    • 5 to 13
    • 14 to18
  • Adult
    • 19 to 44
    • 45+

By Treatment

  • Prophylaxis
  • On Demand 

By Therapy

  • Factor Replacement Therapy
  • Non-factor Replacement Therapy 

By Drug Class

  • Vasopressin
  • Coagulation Factors 

By Route of Administration

  • Injectable
  • Nasal Spray

By End Use

  • Hospitals
  • Clinics
  • Hemophilia Treatment Centers
  • Others

By Region     

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Russia
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
  • Latin America
    • Brazil
    • Mexico
  • MEA
    • Saudi Arabia
    • UAE
    • South Africa

1. Executive Summary
     1.1. Global Hemophilia Treatment Market Outlook, 2019 - 2027 (US$ Million)
     1.2. Global Hemophilia Treatment Market Incremental Opportunity, 2022- 2027 (US$ Million)
     1.3. Key Industry Trends

2. Market Overview
     2.1. Market Definitions and Segmentations
     2.2. Market Dynamics
            2.2.1. Market Drivers
            2.2.2. Market Threats
            2.2.3. Market Opportunities
     2.3. Regulatory Framework
     2.4. Value Framework of Clinical Scenarios
     2.5. Hemophilia Treatment Centres: Comprehensive Care Model
     2.6. Reimbursement Scenario
     2.7. COVID 19 Impact Analysis
     2.8. Hemophilia Market Landscape

3. Global Hemophilia Treatment Market Outlook, 2019 - 2027
     3.1. Global Hemophilia Treatment Market Outlook, By Treatment Type, 2019 - 2027
            3.1.1. Key Highlights
            3.1.2. Global Hemophilia Treatment Market Outlook, by Treatment Type, Value (US$ Million), 2019 - 2027
                   3.1.2.1. Plasma Derived Factor Concentrates
                   3.1.2.2. Recombinant Factor Concentrates
                   3.1.2.3. Alternative Coagulation Promoters
                   3.1.2.4. Others
            3.1.3. Global Hemophilia Treatment Market Share and BPS Analysis, by Treatment Type, Value, 2022 and 2027
            3.1.4. Global Hemophilia Treatment Market Attractiveness Analysis, by Treatment Type, Value, 2022 - 2027
     3.2. Global Hemophilia Treatment Market Outlook, By Indication Type, 2019 - 2027
            3.2.1. Key Highlights
            3.2.2. Global Hemophilia Treatment Market Outlook, by Indication Type, Value (US$ Million), 2019 - 2027
                   3.2.2.1. Hemophilia A
                   3.2.2.2. Hemophilia B
                   3.2.2.3. Acquired Hemophilia
            3.2.3. Global Hemophilia Treatment Market Share and BPS Analysis, by Indication Type, Value, 2022 and 2027
            3.2.4. Global Hemophilia Treatment Market Attractiveness Analysis, by Indication Type, Value, 2022 - 2027
     3.3. Global Hemophilia Treatment Market Outlook, By Application, 2019 - 2027
            3.3.1. Key Highlights
            3.3.2. Global Hemophilia Treatment Market Outlook, by Application, Value (US$ Million), 2019 - 2027
                   3.3.2.1. Prophylaxis
                   3.3.2.2. On Demand
                   3.3.2.3. Surgery
                   3.3.2.4. Immune Tolerance Induction (ITI)
                   3.3.2.5. Others
            3.3.3. Global Hemophilia Treatment Market Share and BPS Analysis, by Application Value, 2022 and 2027
            3.3.4. Global Hemophilia Treatment Market Attractiveness Analysis, by Application, Value 2022 - 2027
     3.4. Global Hemophilia Treatment Market Outlook, By Region, 2019 - 2027
            3.4.1. Key Highlights
            3.4.2. Global Hemophilia Treatment Market Outlook, by Region, Value (US$ Million), 2019 - 2027
                   3.4.2.1. North America
                   3.4.2.2. Europe
                   3.4.2.3. Asia Pacific
                   3.4.2.4. Rest of the World
            3.4.3. Global Hemophilia Treatment Market Share and BPS Analysis, by Region, Value, 2022 and 2027
            3.4.4. Global Hemophilia Treatment Market Attractiveness Analysis, by Region, Value, 2022 - 2027

4. North America Hemophilia Treatment Market Outlook, 2019 - 2027
     4.1. North America Hemophilia Treatment Market Outlook, By Treatment Type, 2019 - 2027
            4.1.1. Key Highlights
            4.1.2. North America Hemophilia Treatment Market Outlook, by Country, Value (US$ Million), 2019 - 2027
                   4.1.2.1. U.S.
                   4.1.2.2. Canada
            4.1.3. North America Hemophilia Treatment Market Outlook, by Treatment Type, Value (US$ Million), 2019 - 2027
                   4.1.3.1. Plasma Derived Factor Concentrates
                   4.1.3.2. Recombinant Factor Concentrates
                   4.1.3.3. Alternative Coagulation Promotors
                   4.1.3.4. Others
            4.1.4. North America Hemophilia Treatment Market Share and BPS Analysis, by Treatment Type, Value, 2022 and 2027
            4.1.5. North America Hemophilia Treatment Market Attractiveness Analysis, by Treatment Type, Value, 2022 - 2027
     4.2. North America Hemophilia Treatment Market Outlook, By Indication Type, 2019 - 2027
            4.2.1. Key Highlights
            4.2.2. North America Hemophilia Treatment Market Outlook, by Indication Type, Value (US$ Million), 2019 - 2027
                   4.2.2.1. Hemophilia A
                   4.2.2.2. Hemophilia B
                   4.2.2.3. Acquired Hemophilia
            4.2.3. North America Hemophilia Treatment Market Share and BPS Analysis, by Indication Value, 2022 and 2027
            4.2.4. North America Hemophilia Treatment Market Attractiveness Analysis, by Indication Type Value, 2022 - 2027
     4.3. North America Hemophilia Treatment Market Outlook, By Application, 2019 - 2027
            4.3.1. Key Highlights
            4.3.2. North America Hemophilia Treatment Market Outlook, by Application, Value (US$ Million) 2019 - 2027
                   4.3.2.1. Prophylaxis
                   4.3.2.2. On Demand
                   4.3.2.3. Surgery
                   4.3.2.4. Immune Tolerance Induction (ITI)
                   4.3.2.5. Others
            4.3.3. North America Hemophilia Treatment Market Share and BPS Analysis, by Application, Value, 2022 and 2027
            4.3.4. North America Hemophilia Treatment Market Attractiveness Analysis, by Application, Value, 2022 - 2027

5. Europe Hemophilia Treatment Market Outlook, 2019 - 2027
     5.1. Europe Hemophilia Treatment Market Outlook, By Treatment Type, 2019 - 2027
            5.1.1. Key Highlights
            5.1.2. Europe Hemophilia Treatment Market Outlook, by Country, Value (US$ Million), 2019 - 2027
                   5.1.2.1. U.K.
                   5.1.2.2. France
                   5.1.2.3. Germany
                   5.1.2.4. Italy
                   5.1.2.5. Spain
                   5.1.2.6. Rest of Europe
            5.1.3. Europe Hemophilia Treatment Market Outlook, by Treatment Type, Value (US$ Million), 2019 - 2027
                   5.1.3.1. Plasma Derived Factor Concentrates
                   5.1.3.2. Recombinant Factor Concentrates
                   5.1.3.3. Alternative Coagulation Promotors
                   5.1.3.4. Others
            5.1.4. Europe Hemophilia Treatment Market Share and BPS Analysis, by Treatment Type, Value, 2022 and 2027
            5.1.5. Europe Hemophilia Treatment Market Attractiveness Analysis, by Treatment Type, Value, 2022 - 2027
     5.2. Europe Hemophilia Treatment Market Outlook, By Indication Type, 2019 - 2027
            5.2.1. Key Highlights
            5.2.2. Europe Hemophilia Treatment Market Outlook, by Indication Type, Value (US$ Million), 2019 - 2027
                   5.2.2.1. Hemophilia A
                   5.2.2.2. Hemophilia B
                   5.2.2.3. Acquired Hemophilia
            5.2.3. Europe Hemophilia Treatment Market Share and BPS Analysis, by Indication Value, 2022 and 2027
            5.2.4. Europe Hemophilia Treatment Market Attractiveness Analysis, by Indication Type Value, 2022 - 2027
     5.3. Europe Hemophilia Treatment Market Outlook, By Application, 2019 - 2027
            5.3.1. Key Highlights
            5.3.2. Europe Hemophilia Treatment Market Outlook, by Application, Value (US$ Million) 2019 - 2027
                   5.3.2.1. Prophylaxis
                   5.3.2.2. On Demand
                   5.3.2.3. Surgery
                   5.3.2.4. Immune Tolerance Induction (ITI)
                   5.3.2.5. Others
            5.3.3. Europe Hemophilia Treatment Market Share and BPS Analysis, by Application, Value, 2022 and 2027
            5.3.4. Europe Hemophilia Treatment Market Attractiveness Analysis, by Application, Value, 2022 - 2027

6. Asia Pacific Hemophilia Treatment Market Outlook, 2019 - 2027
     6.1. Asia Pacific Hemophilia Treatment Market Outlook, By Treatment Type, 2019 - 2027
            6.1.1. Key Highlights
            6.1.2. Asia Pacific Hemophilia Treatment Market Outlook, by Country, Value (US$ Million), 2019 - 2027
                   6.1.2.1. India
                   6.1.2.2. Japan
                   6.1.2.3. China
                   6.1.2.4. Australia
                   6.1.2.5. Rest of Asia Pacific
            6.1.3. Asia Pacific Hemophilia Treatment Market Outlook, by Treatment Type, Value (US$ Million), 2019 - 2027
                   6.1.3.1. Plasma Derived Factor Concentrates
                   6.1.3.2. Recombinant Factor Concentrates
                   6.1.3.3. Alternative Coagulation Promotors
                   6.1.3.4. Others
            6.1.4. Asia Pacific Hemophilia Treatment Market Share and BPS Analysis, by Treatment Type, Value, 2022 and 2027
            6.1.5. Asia Pacific Hemophilia Treatment Market Attractiveness Analysis, by Treatment Type, Value, 2022 - 2027
     6.2. Asia Pacific Hemophilia Treatment Market Outlook, By Indication Type, 2019 - 2027
            6.2.1. Key Highlights
            6.2.2. Asia Pacific Hemophilia Treatment Market Outlook, by Indication Type, Value (US$ Million), 2019 - 2027
                   6.2.2.1. Hemophilia A
                   6.2.2.2. Hemophilia B
                   6.2.2.3. Acquired Hemophilia
            6.2.3. Asia Pacific Hemophilia Treatment Market Share and BPS Analysis, by Indication Value, 2022 and 2027
            6.2.4. Asia Pacific Hemophilia Treatment Market Attractiveness Analysis, by Indication Type Value, 2022 - 2027
     6.3. Asia Pacific Hemophilia Treatment Market Outlook, By Application, 2019 - 2027
            6.3.1. Key Highlights
            6.3.2. Asia Pacific Hemophilia Treatment Market Outlook, by Application, Value (US$ Million) 2019 - 2027
                   6.3.2.1. Prophylaxis
                   6.3.2.2. On Demand
                   6.3.2.3. Surgery
                   6.3.2.4. Immune Tolerance Induction (ITI)
                   6.3.2.5. Others
            6.3.3. Asia Pacific Hemophilia Treatment Market Share and BPS Analysis, by Application, Value, 2022 and 2027
            6.3.4. Asia Pacific Hemophilia Treatment Market Attractiveness Analysis, by Application, Value, 2022 - 2027

7. Rest of the World Hemophilia Treatment Market Outlook, 2019 - 2027
     7.1. Rest of the World Hemophilia Treatment Market Outlook, By Treatment Type, 2019 - 2027
            7.1.1. Key Highlights
            7.1.2. Rest of the World Hemophilia Treatment Market Outlook, by Country, Value (US$ Million), 2019 - 2027
                   7.1.2.1. Latin America
                   7.1.2.2. Middle East & Africa
            7.1.3. Rest of the World Hemophilia Treatment Market Outlook, by Treatment Type, Value (US$ Million), 2019 - 2027
                   7.1.3.1. Plasma Derived Factor Concentrates
                   7.1.3.2. Recombinant Factor Concentrates
                   7.1.3.3. Alternative Coagulation Promotors
                   7.1.3.4. Others
            7.1.4. Rest of the World Hemophilia Treatment Market Share and BPS Analysis, by Treatment Type, Value, 2022 and 2027
            7.1.5. Rest of the World Hemophilia Treatment Market Attractiveness Analysis, by Treatment Type, Value, 2022 - 2027
     7.2. Rest of the World Hemophilia Treatment Market Outlook, By Indication Type, 2019 - 2027
            7.2.1. Key Highlights
            7.2.2. Rest of the World Hemophilia Treatment Market Outlook, by Indication Type, Value (US$ Million), 2019 - 2027
                   7.2.2.1. Hemophilia A
                   7.2.2.2. Hemophilia B
                   7.2.2.3. Acquired Hemophilia
            7.2.3. Rest of the World Hemophilia Treatment Market Share and BPS Analysis, by Indication Value, 2022 and 2027
            7.2.4. Rest of the World Hemophilia Treatment Market Attractiveness Analysis, by Indication Type Value, 2022 - 2027
     7.3. Rest of the World Hemophilia Treatment Market Outlook, By Application, 2019 - 2027
            7.3.1. Key Highlights
            7.3.2. Rest of the World Hemophilia Treatment Market Outlook, by Application, Value (US$ Million) 2019 - 2027
                   7.3.2.1. Prophylaxis
                   7.3.2.2. On Demand
                   7.3.2.3. Surgery
                   7.3.2.4. Immune Tolerance Induction (ITI)
                   7.3.2.5. Others
            7.3.3. Rest of the World Hemophilia Treatment Market Share and BPS Analysis, by Application, Value, 2022 and 2027
            7.3.4. Rest of the World Hemophilia Treatment Market Attractiveness Analysis, by Application, Value, 2022 - 2027

8. Competitive Landscape
     8.1. Market Share Analysis, 2021
     8.2. Company Profiles
            8.2.1. Bayer AG
                   8.2.1.1. Company overview
                   8.2.1.2. Financial performance
                   8.2.1.3. Product Portfolio
                   8.2.1.4. Pipeline Analysis
Above details will include, but not be limited to below list of companies based on availability
            8.2.2. BioMarin Pharmaceuticals, Inc.
            8.2.3. F. Hoffman La Roche Ltd.
            8.2.4. Grifols S.A.
            8.2.5. Sanofi
            8.2.6. Takeda Pharmaceuticals Company Ltd.
            8.2.7. CSL Behring
            8.2.8. Medexus Pharmaceuticals Inc.
            8.2.9. Novo Nordisk
            8.2.10. Octapharma AG
            8.2.11. Pfizer Inc.

9. Appendix
     9.1. Research Methodology
     9.2. Report Specific Research Approach

BASE YEAR

HISTORICAL DATA

FORECAST PERIOD

UNITS

2021

2019 - 2020

   2022 - 2027 


Value: US$ Million

 

 

REPORT FEATURES

DETAILS

Treatment Type

  • Plasma Derived Factor Concentrates
  • Recombinant Factor Concentrates
  • Alternate Coagulation Promoters
  • Others

Indication Type

  • Hemophilia A
  • Hemophilia B
  • Acquired Hemophilia

Application

  • Prophylaxis
  • On Demand
  • Surgery
  • Immune Tolerance Induction (ITI)
  • Others

Geographic Coverage

  • North America
  • United States
  • Canada
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia Pacific
  • Rest of the World
  • Latin America
  • Middle East and Africa

Leading Companies

  • Bayer AG
  • BioMarin Pharmaceuticals, Inc.
  • F. Hoffman La Roche Ltd.
  • Grifols S.A.
  • Sanofi
  • Takeda Pharmaceuticals Company Ltd.
  • CSL Behring
  • Medexus Pharmaceuticals Inc.
  • Novo Nordisk
  • Octapharma AG
  • Pfizer Inc.

  Report Highlights

Key Market Indicators, Market Estimates and Forecast (Value), Market Dynamics, Regulatory Guidelines, COVID-19 Impact Analysis, Regional and Country Insights, Competitive Landscape, Company Profiles

FAQs : Hemophilia Treatment Market

Global Hemophilia Treatment Market is anticipated to reach US$ 21,349.6 Million indicating introduction of advanced treatment options driving the market growth.

Global Hemophilia Treatment Market is anticipated to witness CAGR of 5.2% through the forecast period 2022-2027 and reach US$ 21,346.60 Million by 2027 from US$ 16,565.5 Million in 2022.

North America leads the Global Hemophilia Treatment Market in terms of value. The region will continue to lead its way through the forecast period to reach the value of US$ 7,899 Million by 2027. Presence of major players in the region will contribute to the largest revenue share of the region.

Recombinant Factor Concentrates segment is anticipated to dominate the Global Hemophilia Treatment Market by 2027 with contribution of ~40% .

Prophylaxis segment is anticipated to dominate the Global Hemophilia Treatment Market in terms of value by 2027 witnessing highest growth rate with contribution of ~40% market share.

Our Research Methodology

Under uncertainty, traditional approaches to strategic planning can be downright dangerous. True ambiguity is no basis to forecast the future – degree of risk, the magnitude of circumstances, conditions and consequences are not known or unpredictable. To avoid dangerous binary views of uncertainty; strategic posture, moves and actions through market research is the best bet.

Read more
Fairfield Quality assured
Fairfield Confidentiality assured
Fairfield Custom research services